JP2013505950A - 代謝疾患の予防および治療のための組成物および方法 - Google Patents
代謝疾患の予防および治療のための組成物および方法 Download PDFInfo
- Publication number
- JP2013505950A JP2013505950A JP2012531070A JP2012531070A JP2013505950A JP 2013505950 A JP2013505950 A JP 2013505950A JP 2012531070 A JP2012531070 A JP 2012531070A JP 2012531070 A JP2012531070 A JP 2012531070A JP 2013505950 A JP2013505950 A JP 2013505950A
- Authority
- JP
- Japan
- Prior art keywords
- bone
- milk
- derived
- whey
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 title claims description 32
- 208000030159 metabolic disease Diseases 0.000 title abstract description 4
- 230000002265 prevention Effects 0.000 title description 4
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 59
- 230000024279 bone resorption Effects 0.000 claims abstract description 34
- 208000006386 Bone Resorption Diseases 0.000 claims abstract description 33
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 33
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 31
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 239000005862 Whey Substances 0.000 claims abstract description 24
- 235000013336 milk Nutrition 0.000 claims description 34
- 239000008267 milk Substances 0.000 claims description 34
- 210000004080 milk Anatomy 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 32
- 239000011707 mineral Substances 0.000 claims description 32
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 30
- 208000001132 Osteoporosis Diseases 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 13
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 12
- 238000002441 X-ray diffraction Methods 0.000 claims description 11
- 239000002131 composite material Substances 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 102000002322 Egg Proteins Human genes 0.000 claims description 5
- 108010000912 Egg Proteins Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 3
- 210000003278 egg shell Anatomy 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 229910001575 sodium mineral Inorganic materials 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims 7
- 239000012460 protein solution Substances 0.000 claims 3
- 208000036119 Frailty Diseases 0.000 claims 2
- 206010003549 asthenia Diseases 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000030991 negative regulation of bone resorption Effects 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 abstract description 41
- 229910052588 hydroxylapatite Inorganic materials 0.000 abstract description 34
- 235000018102 proteins Nutrition 0.000 abstract description 26
- 108010035532 Collagen Proteins 0.000 abstract description 16
- 102000008186 Collagen Human genes 0.000 abstract description 16
- 229920001436 collagen Polymers 0.000 abstract description 16
- 239000011159 matrix material Substances 0.000 abstract description 13
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract description 10
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract description 10
- 229940112869 bone morphogenetic protein Drugs 0.000 abstract description 10
- 238000012423 maintenance Methods 0.000 abstract description 9
- 235000021119 whey protein Nutrition 0.000 abstract description 9
- 230000006378 damage Effects 0.000 abstract description 8
- 230000035876 healing Effects 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 230000008439 repair process Effects 0.000 abstract description 6
- 210000002435 tendon Anatomy 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 101000995928 Mus musculus Nucleolar protein 58 Proteins 0.000 abstract description 3
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 abstract description 3
- 230000037180 bone health Effects 0.000 abstract description 3
- 230000001419 dependent effect Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 description 32
- 239000011575 calcium Substances 0.000 description 22
- 235000010755 mineral Nutrition 0.000 description 22
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 22
- 229910052586 apatite Inorganic materials 0.000 description 19
- 206010065687 Bone loss Diseases 0.000 description 18
- 239000002121 nanofiber Substances 0.000 description 17
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 206010017076 Fracture Diseases 0.000 description 11
- 229960005069 calcium Drugs 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- 230000011164 ossification Effects 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000003917 TEM image Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 208000010392 Bone Fractures Diseases 0.000 description 8
- 229910000019 calcium carbonate Inorganic materials 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102000011632 Caseins Human genes 0.000 description 7
- 108010076119 Caseins Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108010022452 Collagen Type I Proteins 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 102000004407 Lactalbumin Human genes 0.000 description 5
- 108090000942 Lactalbumin Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 230000008416 bone turnover Effects 0.000 description 4
- 229940069978 calcium supplement Drugs 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000006911 nucleation Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 239000011368 organic material Substances 0.000 description 4
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 3
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 3
- 102000010445 Lactoferrin Human genes 0.000 description 3
- 108010063045 Lactoferrin Proteins 0.000 description 3
- 102000008192 Lactoglobulins Human genes 0.000 description 3
- 108010060630 Lactoglobulins Proteins 0.000 description 3
- 108010023244 Lactoperoxidase Proteins 0.000 description 3
- 102000045576 Lactoperoxidases Human genes 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108010001441 Phosphopeptides Proteins 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000037176 bone building Effects 0.000 description 3
- 230000008468 bone growth Effects 0.000 description 3
- 230000010072 bone remodeling Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229940001490 fosamax Drugs 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 3
- 235000021242 lactoferrin Nutrition 0.000 description 3
- 229940078795 lactoferrin Drugs 0.000 description 3
- 229940057428 lactoperoxidase Drugs 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 102000007584 Prealbumin Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037118 bone strength Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 101150026046 iga gene Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 239000002114 nanocomposite Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000021249 α-casein Nutrition 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 101800000112 Acidic peptide Proteins 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010073767 Developmental hip dysplasia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000007446 Hip Dislocation Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 238000003991 Rietveld refinement Methods 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000036426 canine hip dysplasia Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 1
- 229910052587 fluorapatite Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000000324 molecular mechanic Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 101150082630 pdf-2 gene Proteins 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
- A23C9/1425—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of whey, e.g. treatment of the UF permeate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
- A23C9/1427—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by dialysis, reverse osmosis or hyperfiltration, e.g. for concentrating or desalting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/146—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by ion-exchange
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
- A23K10/26—Animal feeding-stuffs from material of animal origin from waste material, e.g. feathers, bones or skin
- A23K10/28—Animal feeding-stuffs from material of animal origin from waste material, e.g. feathers, bones or skin from waste dairy products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/42—Dry feed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Water Supply & Treatment (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24550509P | 2009-09-24 | 2009-09-24 | |
| US61/245,505 | 2009-09-24 | ||
| PCT/US2010/050202 WO2011038230A2 (en) | 2009-09-24 | 2010-09-24 | Compositions and methods for the prevention and treatment of metabolic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505950A true JP2013505950A (ja) | 2013-02-21 |
| JP2013505950A5 JP2013505950A5 (enExample) | 2013-11-14 |
Family
ID=43796456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012531070A Pending JP2013505950A (ja) | 2009-09-24 | 2010-09-24 | 代謝疾患の予防および治療のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US8518453B2 (enExample) |
| EP (1) | EP2480099B1 (enExample) |
| JP (1) | JP2013505950A (enExample) |
| AU (1) | AU2010298141B2 (enExample) |
| CA (1) | CA2775276C (enExample) |
| NZ (1) | NZ599184A (enExample) |
| RU (1) | RU2565020C2 (enExample) |
| WO (2) | WO2011037957A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011037957A2 (en) | 2009-09-24 | 2011-03-31 | U.S. Foods & Pharmaceuticals, Inc. | Compositions and methods for bone repair, maintenance and regeneration |
| CN103599521A (zh) * | 2013-11-08 | 2014-02-26 | 苏州冉新生物技术有限公司 | 一种复合维生素d冲剂 |
| BE1027357B1 (nl) * | 2019-06-12 | 2021-01-18 | Vanlommel Maria Kristel | Voedingssupplement voor versnelde genezing |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733668A (ja) * | 1993-07-21 | 1995-02-03 | Maruha Corp | 骨強化促進剤 |
| JPH099864A (ja) * | 1995-06-29 | 1997-01-14 | Snow Brand Milk Prod Co Ltd | 乳由来カルシウム含有組成物及びその製造方法 |
| US5639501A (en) * | 1995-01-31 | 1997-06-17 | Vembu; Rajan | Separation of minerals from whey permeate |
| JP2000281587A (ja) * | 1999-03-30 | 2000-10-10 | Snow Brand Milk Prod Co Ltd | 骨吸収抑制剤 |
| JP2001346519A (ja) * | 2000-06-09 | 2001-12-18 | Snow Brand Milk Prod Co Ltd | 乳塩基性シスタチン高含有画分及びその分解物の製造方法 |
| JP2002000193A (ja) * | 2000-06-20 | 2002-01-08 | Snow Brand Milk Prod Co Ltd | 乳塩基性シスタチン高含有画分及びその分解物の製造法 |
| JP2004115509A (ja) * | 2002-09-05 | 2004-04-15 | Snow Brand Milk Prod Co Ltd | 破骨細胞分化抑制因子産生促進剤 |
| JP2005060321A (ja) * | 2003-08-15 | 2005-03-10 | Snow Brand Milk Prod Co Ltd | 骨形成促進剤 |
| JP2007512374A (ja) * | 2003-11-26 | 2007-05-17 | デピュイ・スパイン・インコーポレイテッド | 骨形成剤および吸収抑制剤の局所骨内投与、並びにそのための装置 |
| WO2008028194A2 (en) * | 2006-09-01 | 2008-03-06 | Cornell Research Foundation, Inc. | Calcium phosphate nanofibers |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3615664A (en) * | 1969-12-05 | 1971-10-26 | Foremost Mckesson | Treatment of whey |
| US3896241A (en) * | 1971-09-01 | 1975-07-22 | Coca Cola Co | Preparation of a whey protein concentrate |
| US4572837A (en) * | 1984-06-28 | 1986-02-25 | The British Food Manufacturing Industries Research Association | Protein product |
| NL9001692A (nl) * | 1990-04-26 | 1991-11-18 | Cooeperatieve Melkproductenbed | Werkwijze voor de bereiding van een olie-in-water emulsie. |
| EP0545946B1 (en) * | 1990-07-13 | 2005-01-19 | Gropep Limited | Growth-promoting agent |
| US7033610B2 (en) * | 1990-07-13 | 2006-04-25 | Gropep Pty, Ltd. | Growth-promoting agent |
| JP3604159B2 (ja) * | 1992-05-07 | 2004-12-22 | 雪印乳業株式会社 | 乳清由来の骨芽細胞増殖促進及び骨強化因子ならびに該因子を含有せしめた骨強化食品、医薬および飼料 |
| US5912032A (en) * | 1995-05-11 | 1999-06-15 | Meiji Milk Products Company, Limited | Process of producing calcium-supplemented milk drinks |
| JP2974604B2 (ja) * | 1996-01-23 | 1999-11-10 | 雪印乳業株式会社 | 塩基性タンパク質組成物、塩基性ペプチド組成物及びその利用 |
| US6139901A (en) * | 1997-09-16 | 2000-10-31 | New Zealand Milk Products (North Amerca) Inc. | Membrane filtered milk proteins varying in composition and functional attributes |
| JP4701472B2 (ja) * | 2000-04-21 | 2011-06-15 | 雪印乳業株式会社 | 乳カルシウム組成物の製造方法 |
| AU784087B2 (en) * | 2000-06-09 | 2006-02-02 | Megmilk Snow Brand Co., Ltd. | Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof |
| NZ507335A (en) * | 2000-10-05 | 2004-10-29 | New Zealand Dairy Board | Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP |
| US20030026845A1 (en) * | 2001-06-18 | 2003-02-06 | Etzel Lisa R. | Process for preparing protein isolate from milk, whey, colostrum, and the like |
| US20030118662A1 (en) * | 2001-12-05 | 2003-06-26 | Glanbia Foods, Inc. | Therapeutic uses of milk mineral fortified food products |
| FR2841747B1 (fr) * | 2002-07-02 | 2004-08-20 | Cie Laitiere Europeenne | Isolat de proteines de lait et procede pour sa preparation |
| KR100509177B1 (ko) * | 2003-02-05 | 2005-08-22 | 롯데제과주식회사 | 골다공증 예방용 기능성 식품 조성물 |
| US20050208638A1 (en) * | 2004-03-22 | 2005-09-22 | Chao Wu | Process for preparing bioactive protein-enriched whey products |
| WO2006058083A2 (en) * | 2004-11-24 | 2006-06-01 | Cornell Research Foundation, Inc. | Protein and calcium fortification system for clear and opaque beverages |
| ZA200804292B (en) * | 2005-11-30 | 2009-09-30 | Unilever Plc | Calcium fortified food product and additive |
| DE102006009799A1 (de) * | 2006-03-01 | 2007-09-06 | Henkel Kgaa | Vorwiegend plättchenförmige schwer wasserlösliche Calciumsalze und/oder deren Kompositmaterialien, umfassend diese |
| FR2901796A1 (fr) * | 2006-05-31 | 2007-12-07 | Lab Francais Du Fractionnement | Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait |
| JP5657200B2 (ja) * | 2008-09-05 | 2015-01-21 | サントリー食品インターナショナル株式会社 | 乳清タンパク質の含有量が低減された乳組成物及び乳入り飲料 |
| WO2011037957A2 (en) | 2009-09-24 | 2011-03-31 | U.S. Foods & Pharmaceuticals, Inc. | Compositions and methods for bone repair, maintenance and regeneration |
-
2010
- 2010-09-22 WO PCT/US2010/049757 patent/WO2011037957A2/en not_active Ceased
- 2010-09-24 JP JP2012531070A patent/JP2013505950A/ja active Pending
- 2010-09-24 RU RU2012114489/13A patent/RU2565020C2/ru active
- 2010-09-24 EP EP10819532.2A patent/EP2480099B1/en not_active Not-in-force
- 2010-09-24 NZ NZ599184A patent/NZ599184A/xx not_active IP Right Cessation
- 2010-09-24 CA CA2775276A patent/CA2775276C/en active Active
- 2010-09-24 US US12/890,090 patent/US8518453B2/en not_active Expired - Fee Related
- 2010-09-24 AU AU2010298141A patent/AU2010298141B2/en not_active Ceased
- 2010-09-24 WO PCT/US2010/050202 patent/WO2011038230A2/en not_active Ceased
-
2012
- 2012-08-06 US US13/567,727 patent/US8557296B2/en not_active Expired - Fee Related
-
2013
- 2013-10-10 US US14/050,810 patent/US20140227409A1/en not_active Abandoned
-
2016
- 2016-03-02 US US15/058,452 patent/US20170027989A1/en not_active Abandoned
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733668A (ja) * | 1993-07-21 | 1995-02-03 | Maruha Corp | 骨強化促進剤 |
| US5639501A (en) * | 1995-01-31 | 1997-06-17 | Vembu; Rajan | Separation of minerals from whey permeate |
| JPH099864A (ja) * | 1995-06-29 | 1997-01-14 | Snow Brand Milk Prod Co Ltd | 乳由来カルシウム含有組成物及びその製造方法 |
| JP2000281587A (ja) * | 1999-03-30 | 2000-10-10 | Snow Brand Milk Prod Co Ltd | 骨吸収抑制剤 |
| JP2001346519A (ja) * | 2000-06-09 | 2001-12-18 | Snow Brand Milk Prod Co Ltd | 乳塩基性シスタチン高含有画分及びその分解物の製造方法 |
| JP2002000193A (ja) * | 2000-06-20 | 2002-01-08 | Snow Brand Milk Prod Co Ltd | 乳塩基性シスタチン高含有画分及びその分解物の製造法 |
| JP2004115509A (ja) * | 2002-09-05 | 2004-04-15 | Snow Brand Milk Prod Co Ltd | 破骨細胞分化抑制因子産生促進剤 |
| JP2005060321A (ja) * | 2003-08-15 | 2005-03-10 | Snow Brand Milk Prod Co Ltd | 骨形成促進剤 |
| JP2007512374A (ja) * | 2003-11-26 | 2007-05-17 | デピュイ・スパイン・インコーポレイテッド | 骨形成剤および吸収抑制剤の局所骨内投与、並びにそのための装置 |
| WO2008028194A2 (en) * | 2006-09-01 | 2008-03-06 | Cornell Research Foundation, Inc. | Calcium phosphate nanofibers |
Non-Patent Citations (1)
| Title |
|---|
| JPN6014037631; Biosci. Biotechnol. Biochem., 2007, Vol.71, No.2, pp.336-342 * |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ599184A (en) | 2013-04-26 |
| CA2775276A1 (en) | 2011-03-31 |
| WO2011038230A2 (en) | 2011-03-31 |
| US20110189337A1 (en) | 2011-08-04 |
| WO2011037957A2 (en) | 2011-03-31 |
| EP2480099B1 (en) | 2018-12-12 |
| WO2011038230A3 (en) | 2011-08-11 |
| US20130029017A1 (en) | 2013-01-31 |
| US20140227409A1 (en) | 2014-08-14 |
| US8557296B2 (en) | 2013-10-15 |
| US20170027989A1 (en) | 2017-02-02 |
| EP2480099A2 (en) | 2012-08-01 |
| EP2480099A4 (en) | 2015-05-27 |
| RU2012114489A (ru) | 2013-10-27 |
| AU2010298141A1 (en) | 2012-04-19 |
| RU2565020C2 (ru) | 2015-10-10 |
| AU2010298141B2 (en) | 2015-12-17 |
| CA2775276C (en) | 2021-07-06 |
| WO2011037957A3 (en) | 2012-02-23 |
| US8518453B2 (en) | 2013-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120040908A1 (en) | Fracture repair promoter | |
| JP2009107938A (ja) | 生体適合性材料並びにその製造方法 | |
| US20170027989A1 (en) | Compositions and Methods for the Prevention and Treatment of Metabolic Diseases | |
| CN107494963A (zh) | 宠物钙膏及其制备方法 | |
| KR102471621B1 (ko) | 베타-카세인 및 인지 기능 | |
| JP6203724B2 (ja) | 骨疾患の予防又は治療用タンパク質素材及びその製造方法 | |
| ES2370122T3 (es) | Alimento para estimular la diferenciación de osteoblastos e inhibir la diferenciación de osteoclastos. | |
| CN115399370A (zh) | 高钙鲜牛奶及其制备方法和应用 | |
| Chinoy et al. | Current status in therapeutic interventions of neonatal bone mineral metabolic disorders | |
| CN119326037A (zh) | 一种有助于骨骼健康和身高发育的营养组合物及其应用 | |
| CN1293915C (zh) | 减少钙化的动脉斑集结和细胞功能紊乱以及平衡钙离子的方法 | |
| Ghanem et al. | Evaluation of Four Treatment Protocols on Experimentally Induced Nutritional Secondary Hyperparathyroidism in Kittens | |
| Prentice | The effects of silicon on skeletal integrity in poultry | |
| Vujasinović-Stupar et al. | Supplementation with bio-calcium from shells Pinctada maxima in postmenopausal women with decreased mineral bone density: Pilot study | |
| Riccardi et al. | Bone disease and new prevention frontiers chapter one: Osteoporosis | |
| CN111012900A (zh) | 一种具有增加骨密度功能的组合物及其制备方法与应用 | |
| JP6203723B2 (ja) | 骨疾患の予防又は治療用タンパク質素材及びその製造方法 | |
| US20240424066A1 (en) | Chondroprotective Nutraceutical Composition and Method of Using Same | |
| EP3041482B1 (en) | High osteocalcin microcrystalline hydroxyapatite for calcium supplement | |
| Shah et al. | Evaluation of the efficacy and safety of lactoferrin combination in improving bone mineral density in healthy male dogs | |
| McKinnon | Effect of goat milk on bone mass, morphology and biomechanics: a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Anatomy and Physiology at Massey University, Palmerston North, New Zealand | |
| Yumol | Determining If Lowering the Level of Dietary Calcium and Vitamin D in AIN-93G Diet Supports Normal Bone Development and Intestinal Integrity in Female CD-1 Mice | |
| Shidara | Eggshell Calcium | |
| JP6357266B2 (ja) | 骨疾患の予防又は治療用タンパク質素材 | |
| JP6357265B2 (ja) | 骨疾患の予防又は治療用タンパク質素材 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130924 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130924 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140909 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141208 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141215 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160125 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160517 |